Laboratory of Immunoregulation, NIAID, NIH, Baltimore, Maryland, United States of America.
PLoS One. 2013 Jul 11;8(7):e68349. doi: 10.1371/journal.pone.0068349. Print 2013.
National Institute of Mental Health Project Accept (HIV Prevention Trials Network [HPTN] 043) is a large, Phase III, community-randomized, HIV prevention trial conducted in 48 matched communities in Africa and Thailand. The study intervention included enhanced community-based voluntary counseling and testing. The primary endpoint was HIV incidence, assessed in a single, cross-sectional, post-intervention survey of >50,000 participants.
HIV rapid tests were performed in-country. HIV status was confirmed at a central laboratory in the United States. HIV incidence was estimated using a multi-assay algorithm (MAA) that included the BED capture immunoassay, an avidity assay, CD4 cell count, and HIV viral load.
Data from Thailand was not used in the endpoint analysis because HIV prevalence was low. Overall, 7,361 HIV infections were identified (4 acute, 3 early, and 7,354 established infections). Samples from established infections were analyzed using the MAA; 467 MAA positive samples were identified; 29 of those samples were excluded because they contained antiretroviral drugs. HIV prevalence was 16.5% (range at study sites: 5.93% to 30.8%). HIV incidence was 1.60% (range at study sites: 0.78% to 3.90%).
In this community-randomized trial, a MAA was used to estimate HIV incidence in a single, cross-sectional post-intervention survey. Results from this analysis were subsequently used to compare HIV incidence in the control and intervention communities.
ClinicalTrials.gov NCT00203749.
美国国立精神卫生研究所项目接受(HIV 预防试验网络[HPTN]043)是一项大型的 III 期社区随机 HIV 预防试验,在非洲和泰国的 48 个匹配社区中进行。该研究干预措施包括强化社区为基础的自愿咨询和检测。主要终点是 HIV 发病率,在 >50,000 名参与者的单次、横断面、干预后调查中评估。
在国内进行 HIV 快速检测。在位于美国的一个中心实验室确认 HIV 状态。使用多检测算法(MAA)估计 HIV 发病率,该算法包括 BED 捕获免疫测定、亲和力测定、CD4 细胞计数和 HIV 病毒载量。
由于 HIV 流行率低,泰国的数据未用于终点分析。总体而言,确定了 7361 例 HIV 感染(4 例急性、3 例早期和 7354 例已建立感染)。使用 MAA 分析已建立感染的样本;确定了 467 个 MAA 阳性样本;由于其中 29 个样本含有抗逆转录病毒药物,因此将其排除在外。HIV 流行率为 16.5%(研究点范围:5.93%至 30.8%)。HIV 发病率为 1.60%(研究点范围:0.78%至 3.90%)。
在这项社区随机试验中,使用 MAA 来估计单次横断面干预后调查中的 HIV 发病率。随后,该分析的结果用于比较对照组和干预组的 HIV 发病率。
ClinicalTrials.gov NCT00203749。